Makoto Otsu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7070357/publications.pdf

Version: 2024-02-01

92 papers	7,466 citations	172207 29 h-index	54797 84 g-index
96 all docs	96 docs citations	96 times ranked	12843 citing authors

#	Article	IF	Citations
1	CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nature Medicine, 2009, 15, 914-920.	15.2	1,887
2	Frequent pathway mutations of splicing machinery in myelodysplasia. Nature, 2011, 478, 64-69.	13.7	1,764
3	Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature, 2009, 460, 904-908.	13.7	380
4	Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nature Genetics, 2013, 45, 1232-1237.	9.4	334
5	Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells. Journal of Experimental Medicine, 2010, 207, 2817-2830.	4.2	295
6	Adipose Natural Regulatory B Cells Negatively Control Adipose Tissue Inflammation. Cell Metabolism, 2013, 18, 759-766.	7.2	195
7	ACTN1 Mutations Cause Congenital Macrothrombocytopenia. American Journal of Human Genetics, 2013, 92, 431-438.	2.6	186
8	Generation of Engraftable Hematopoietic Stem Cells From Induced Pluripotent Stem Cells by Way of Teratoma Formation. Molecular Therapy, 2013, 21, 1424-1431.	3.7	186
9	X-SCID transgene leukaemogenicity. Nature, 2006, 443, E5-E6.	13.7	144
10	Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples. Blood, 2012, 119, 6234-6242.	0.6	143
11	Somatic mosaicism in Wiskott-Aldrich syndrome suggests in vivo reversion by a DNA slippage mechanism. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 8697-8702.	3.3	137
12	Development of Sendai Virus Vectors and their Potential Applications in Gene Therapy and Regenerative Medicine. Current Gene Therapy, 2012, 12, 410-416.	0.9	102
13	Heterozygous ITGA2B R995W mutation inducing constitutive activation of the Î±IIbÎ²3 receptor affects proplatelet formation and causes congenital macrothrombocytopenia. Blood, 2011, 117, 5479-5484.	0.6	85
14	A Refined Culture System for Human Induced Pluripotent Stem Cell-Derived Intestinal Epithelial Organoids. Stem Cell Reports, 2018, 10, 314-328.	2.3	83
15	Immortalization of Erythroblasts by c-MYC and BCL-XL Enables Large-Scale Erythrocyte Production from Human Pluripotent Stem Cells. Stem Cell Reports, 2013, 1, 499-508.	2.3	72
16	In vivo imaging visualizes discoid platelet aggregations without endothelium disruption and implicates contribution of inflammatory cytokine and integrin signaling. Blood, 2012, 119, e45-e56.	0.6	71
17	Pathological roles of the VEGF/SphK pathway in Niemannâ€“Pick type C neurons. Nature Communications, 2014, 5, 5514.	5.8	61
18	Lymphoid Development and Function in X-Linked Severe Combined Immunodeficiency Mice after Stem Cell Gene Therapy. Molecular Therapy, 2000, 1, 145-153.	3.7	59

#	Article	IF	Citations
19	Congenital amegakaryocytic thrombocytopenia iPS cells exhibit defective MPL-mediated signaling. Journal of Clinical Investigation, 2013, 123, 3802-3814.	3.9	57
20	Reduction of N-Glycolylneuraminic Acid in Human Induced Pluripotent Stem Cells Generated or Cultured under Feeder- and Serum-Free Defined Conditions. PLoS ONE, 2010, 5, e14099.	1.1	48
21	Definitive proof for direct reprogramming of hematopoietic cells to pluripotency. Blood, 2009, 114, 1764-1767.	0.6	47
22	Reciprocal Inflammatory Signaling Between Intestinal Epithelial Cells and Adipocytes in the Absence of Immune Cells. EBioMedicine, 2017, 23, 34-45.	2.7	45
23	Haploinsufficiency of Sf3b1 leads to compromised stem cell function but not to myelodysplasia. Leukemia, 2014, 28, 1844-1850.	3.3	42
24	Conditional rod photoreceptor ablation reveals Sall1 as a microglial marker and regulator of microglial morphology in the retina. Glia, 2016, 64, 2005-2024.	2.5	42
25	Stage-Specific Roles for Cxcr4 Signaling in Murine Hematopoietic Stem/Progenitor Cells in the Process of Bone Marrow Repopulation. Stem Cells, 2014, 32, 1929-1942.	1.4	34
26	Potent Vaccine Therapy with Dendritic Cells Genetically Modified by the Gene-Silencing-Resistant Retroviral Vector GCDNsap. Molecular Therapy, 2006, 13, 301-309.	3.7	33
27	Stem cell therapy: an exercise in patience and prudence. Philosophical Transactions of the Royal Society B: Biological Sciences, 2013, 368, 20110334.	1.8	33
28	T cell growth control using hapten-specific antibody/interleukin-2 receptor chimera. Cytokine, 2009, 46, 127-136.	1.4	32
29	An All-Recombinant Protein-Based Culture System Specifically Identifies Hematopoietic Stem Cell Maintenance Factors. Stem Cell Reports, 2017, 8, 500-508.	2.3	32
30	Deregulated Intracellular Signaling by Mutated c-CBL in Myeloid Neoplasms. Clinical Cancer Research, 2010, 16, 3825-3831.	3.2	31
31	Simple and Robust Differentiation of Human Pluripotent Stem Cells toward Chondrocytes by Two Small-Molecule Compounds. Stem Cell Reports, 2019, 13, 530-544.	2.3	31
32	Molecular analysis of non-syndromic preaxial polydactyly: preaxial polydactyly type-IV and preaxial polydactyly type-I. Clinical Genetics, 2005, 67, 429-433.	1.0	29
33	Robust and highly efficient hiPSC generation from patient non-mobilized peripheral blood-derived CD34+ cells using the auto-erasable Sendai virus vector. Stem Cell Research and Therapy, 2019, 10, 185.	2.4	28
34	Profiling of MicroRNA in Human and Mouse ES and iPS Cells Reveals Overlapping but Distinct MicroRNA Expression Patterns. PLoS ONE, 2013, 8, e73532.	1.1	28
35	Status of KRAS in iPSCs Impacts upon Self-Renewal and DifferentiationÂPropensity. Stem Cell Reports, 2018, 11, 380-394.	2.3	27
36	The generation of induced pluripotent stem cells (iPSCs) from patients with infantile and late-onset types of Pompe disease and the effects of treatment with acid-Î±-glucosidase in Pompe's iPSCs. Molecular Genetics and Metabolism, 2014, 112, 44-48.	0.5	26

#	Article	IF	Citations
37	Generation of Col2a1-EGFP iPS Cells for Monitoring Chondrogenic Differentiation. PLoS ONE, 2013, 8, e74137.	1.1	25
38	Outcomes in Two Japanese Adenosine Deaminase-Deficiency Patients Treated by Stem Cell Gene Therapy with No Cytoreductive Conditioning. Journal of Clinical Immunology, 2015, 35, 384-398.	2.0	25
39	Growth promotion of genetically modified hematopoietic progenitors using an antibody/c-Mpl chimera. Cytokine, 2011, 55, 402-408.	1.4	24
40	Generation of transgenic mouse line expressing Kusabira Orange throughout body, including erythrocytes, by random segregation of provirus method. Biochemical and Biophysical Research Communications, 2013, 435, 586-591.	1.0	24
41	Using patient-derived iPSCs to develop humanized mouse models for chronic myelomonocytic leukemia and therapeutic drug identification, including liposomal clodronate. Scientific Reports, 2018, 8, 15855.	1.6	24
42	Reconstitution of lymphoid development and function in ZAP-70â€“deficient mice following gene transfer into bone marrow cells. Blood, 2002, 100, 1248-1256.	0.6	23
43	Reprogramming adult hematopoietic cells. Current Opinion in Hematology, 2010, 17, 271-275.	1.2	23
44	Pre-Transplantation Blockade of TNF-Î±-Mediated Oxygen Species Accumulation Protects Hematopoietic Stem Cells. Stem Cells, 2017, 35, 989-1002.	1.4	23
45	Generation of induced pluripotent stem cells derived from primary and secondary myelofibrosis patient samples. Experimental Hematology, 2014, 42, 816-825.	0.2	22
46	Lack of dominant-negative effects of a truncated Î³c on retroviral-mediated gene correction of immunodeficient mice. Blood, 2001, 97, 1618-1624.	0.6	21
47	Comparison of Five Retrovirus Vectors Containing the Human IL-2 Receptor Î³ Chain Gene for Their Ability to Restore T and B Lymphocytes in the X-Linked Severe Combined Immunodeficiency Mouse Model. Molecular Therapy, 2001, 3, 565-573.	3.7	20
48	A new red fluorescent protein that allows efficient marking of murine hematopoietic stem cells. Journal of Gene Medicine, 2008, 10, 965-971.	1.4	19
49	Screening of Drugs to Treat 8p11 Myeloproliferative Syndrome Using Patient-Derived Induced Pluripotent Stem Cells with Fusion Gene CEP110-FGFR1. PLoS ONE, 2015, 10, e0120841.	1.1	19
50	Application of Droplet Digital PCR for Estimating Vector Copy Number States in Stem Cell Gene Therapy. Human Gene Therapy Methods, 2016, 27, 197-208.	2.1	19
51	Hes1 promotes blast crisis in chronic myelogenous leukemia through MMP-9 upregulation in leukemic cells. Blood, 2014, 123, 3932-3942.	0.6	18
52	Successful intravenous immunoglobulin therapy for recurrent pneumococcal otitis media in young children. European Journal of Pediatrics, 1994, 153, 174-178.	1.3	17
53	In VivoCompetitive Studies between Normal and Common Î³ Chain-Defective Bone Marrow Cells: Implications for Gene Therapy. Human Gene Therapy, 2000, 11, 2051-2056.	1.4	17
54	The Actin Polymerization Regulator WAVE2 Is Required for Early Bone Marrow Repopulation by Hematopoietic Stem Cells. Stem Cells, 2009, 27, 1120-1129.	1.4	16

#	Article	IF	Citations
55	Characterization of mesenchymal progenitor cells in the crown and root pulp of primary teeth . Biomedical Research, 2015, 36, 31-45.	0.3	16
56	Non-myeloablative preconditioning with ACK2 (anti-c-kit antibody) is efficient in bone marrow transplantation for murine models of mucopolysaccharidosis type II. Molecular Genetics and Metabolism, 2016, 119, 232-238.	0.5	14
57	Functional Analysis of Dendritic Cells Generated from T-iPSCs from CD4+ T Cell Clones of SjÃ¶gren's Syndrome. Stem Cell Reports, 2017, 8, 1155-1163.	2.3	14
58	Functional Analysis of PTH1R Variants Found in Primary Failure of Eruption. Journal of Dental Research, 2020, 99, 429-436.	2.5	14
59	Flow Cytometry Analysis of Adenosine Deaminase (ADA) Expression: A Simple and Reliable Tool for the Assessment of ADA-Deficient Patients Before and After Gene Therapy. Human Gene Therapy, 2002, 13, 425-432.	1.4	13
60	InÂvitro cell subtype-specific transduction of adeno-associated virus in mouse and marmoset retinal explant culture. Biochimie, 2012, 94, 2716-2722.	1.3	13
61	Biological Analysis of SRSF2 Mutations in Leukemogenesis. Blood, 2012, 120, 1282-1282.	0.6	13
62	Gene Therapy in Infants with Severe Combined Immunodeficiency. BioDrugs, 2002, 16, 229-239.	2.2	12
63	Gain-of-function<i>c-CBL</i>mutations associated with uniparental disomy of 11q in myeloid neoplasms. Cell Cycle, 2010, 9, 1051-1056.	1.3	11
64	An assessment of the effects of ectopic gp91phox expression in XCGD iPSC-derived neutrophils. Molecular Therapy - Methods and Clinical Development, 2015, 2, 15046.	1.8	11
65	Effects of enzyme replacement therapy on immune function in ADA deficiency patient. Clinical Immunology, 2015, 161, 391-393.	1.4	10
66	Stable Transgene Expression in Mice Generated from Retrovirally Transduced Embryonic Stem Cells. Molecular Therapy, 2007, 15, 560-565.	3.7	9
67	Nuclear receptor gene alteration in human induced pluripotent stem cells with hepatic differentiation propensity. Hepatology Research, 2014, 44, E408-19.	1.8	9
68	Designing Motif-Engineered Receptors To Elucidate Signaling Molecules Important for Proliferation of Hematopoietic Stem Cells. ACS Synthetic Biology, 2018, 7, 1709-1714.	1.9	9
69	Minimum requirement of donor cells to reduce the glycolipid storage following bone marrow transplantation in a murine model of Fabry disease. Journal of Gene Medicine, 2011, 13, 262-268.	1.4	8
70	DNA Methylation Is Involved in the Expression of miR-142-3p in Fibroblasts and Induced Pluripotent Stem Cells. Stem Cells International, 2014, 2014, 1-8.	1.2	8
71	Frequent Pathway Mutations of Splicing Machinery in Myelodysplasia. Blood, 2011, 118, 458-458.	0.6	8
72	Effect of donor chimerism to reduce the level of glycosaminoglycans following bone marrow transplantation in a murine model of mucopolysaccharidosis type II. Journal of Inherited Metabolic Disease, 2015, 38, 333-340.	1.7	7

#	Article	IF	Citations
73	A convenient method for positive selection of retroviral producing cells generating vectors devoid of selectable markers. Journal of Virological Methods, 2004, 118, 61-67.	1.0	6
74	A case of C3 deficiency with a novel homozygous two-base deletion in theC3 gene. American Journal of Medical Genetics, Part A, 2005, 138A, 399-400.	0.7	6
75	Detection of a novel silent deletion, a missense mutation and a nonsense mutation in TCOF1. Pediatrics International, 2008, 50, 806-809.	0.2	6
76	Multiple allogeneic progenitors in combination function as a unit to support early transient hematopoiesis in transplantation. Journal of Experimental Medicine, 2016, 213, 1865-1880.	4.2	6
77	Dissection of Signaling Events Downstream of the c-Mpl Receptor in Murine Hematopoietic Stem Cells Via Motif-Engineered Chimeric Receptors. Stem Cell Reviews and Reports, 2018, 14, 101-109.	5.6	5
78	Nonconditioned ADA-SCID gene therapy reveals ADA requirement in the hematopoietic system and clonal dominance of vector-marked clones. Molecular Therapy - Methods and Clinical Development, 2021, 23, 424-433.	1.8	5
79	Gene therapy for primary immune deficiencies. Current Opinion in Allergy and Clinical Immunology, 2001, 1, 497-501.	1.1	4
80	Generation of three induced pluripotent stem cell lines from postmortem tissue derived following sudden death of a young patient with STXBP1 mutation. Stem Cell Research, 2019, 39, 101485.	0.3	4
81	Kinetics and Effect of Integrin Expression on Human CD34+Cells During Murine Leukemia Virus-Derived Retroviral Transduction with Recombinant Fibronectin for Stem Cell Gene Therapy. Human Gene Therapy, 2009, 20, 777-783.	1.4	3
82	Top-down motif engineering of a cytokine receptor for directing ex vivo expansion of hematopoietic stem cells. Journal of Biotechnology, 2013, 168, 659-665.	1.9	3
83	Intracellular estrogen receptor-binding fragment-associated antigen 9 exerts in vivo tumor-promoting effects via its coiled-coil region. International Journal of Oncology, 2011, 39, 41-9.	1.4	2
84	Perspectives on stem cell gene therapy for genetic disorders. ISBT Science Series, 2015, 10, 231-234.	1.1	2
85	Reactive oxygen species in hematopoietic stem cells affect culture outcomes under inflammatory conditions. Open Journal of Hematology, 2015, 6, 1.	0.4	2
86	Curative haploidentical BMT in a murine model of X-linked chronic granulomatous disease. International Journal of Hematology, 2015, 102, 111-120.	0.7	1
87	Transient activation ofc-MYCexpression is critical for efficient platelet generation from human induced pluripotent stem cells. Journal of Cell Biology, 2010, 191, i11-i11.	2.3	1
88	Stem Cell Gene Therapy for ADA-Deficiency without Myelopreparative Conditioning. , 2007, , 1-18.		1
89	Unique Gain-of-Function of Mutated c-CBL Tumor Suppresor in Myeloid Neoplasms.. Blood, 2009, 114, 2970-2970.	0.6	0
90	A New Strategy to Overcome the Cell Dose Barrier to Umbilical Cord Blood Transplants: A Proof of Early Hematopoietic Reconstitution By Combined Multiple Units of Allogeneic Stem/Progenitor Cells. Blood, 2014, 124, 3810-3810.	0.6	0

#	Article	IF	Citations
91	Proof of Benefit in Multiple-Cord Blood Transplantation Evidenced By Early Hematopoietic Reconstitution. Blood, 2015, 126, 3071-3071.	0.6	0
92	Enhanced Selective Inhibition of KRAS Mutant Hematopoietic Progenitor Cell Expansion By MEK and Bcl-2 Inhibition. Blood, 2018, 132, 1278-1278.	0.6	0